Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

NCT00913913 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped low accrual not allowing site to meeting statistical endpoints

Conditions

Metastatic Renal Cell Carcinoma

Interventions

BIOLOGICAL: DC vaccine
DRUG: Bevacizumab
BIOLOGICAL: IL-2
BIOLOGICAL: IFN

Sponsor

Dartmouth-Hitchcock Medical Center

Collaborators

[object Object]